ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Clinical trials for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) explained in plain language.
Never miss a new study
Get alerted when new ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) trials appear
Sign up with your email to follow new studies for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a nerve pain drug calm rosacea Flare-Ups?
Symptom relief CompletedThis study tested whether gabapentin, a drug usually used for nerve pain, can reduce facial flushing and redness in people with rosacea. Fifty adults with rosacea took either gabapentin or a standard treatment for 12 weeks. Researchers measured changes in redness using a doctor-r…
Matched conditions: ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Phase: PHASE1 • Sponsor: First Affiliated Hospital of Chongqing Medical University • Aim: Symptom relief
Last updated May 17, 2026 10:47 UTC
-
Rosacea redness gel shows promise in small study
Symptom relief CompletedThis study tested a gel called brimonidine to see if it can reduce persistent facial redness in people with rosacea. 45 adults took part, using the gel on one side of their face for a day and then on both sides for a month. Redness was measured with a special device and by lookin…
Matched conditions: ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Phase: PHASE4 • Sponsor: Istanbul Training and Research Hospital • Aim: Symptom relief
Last updated May 14, 2026 12:02 UTC